Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae-Reference-Cited by-同舟云学术

Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae

Published:2018-12 Issue:12 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Scangarella-Oman Nicole E.¹,Hossain Mohammad¹,Dixon Paula B.²,Ingraham Karen¹,Min Sharon¹,Tiffany Courtney A.¹,Perry Caroline R.¹,Raychaudhuri Aparna¹,Dumont Etienne F.¹,Huang Jianzhong¹,Hook Edward W.²,Miller Linda A.¹

Affiliation:

1. GlaxoSmithKline, Upper Providence, Pennsylvania, USA

2. University of Alabama at Birmingham, Birmingham, Alabama, USA

Abstract

We evaluated microbiological correlates for the successful treatment of Neisseria gonorrhoeae isolates from a phase 2 study of gepotidacin, a novel triazaacenaphthylene antibacterial, for therapy of uncomplicated urogenital gonorrhea. Culture, susceptibility testing, genotypic characterization, and frequency of resistance (FoR) were performed for selected isolates.

Funder

GlaxoSmithKline

HHS | Biomedical Advanced Research and Development Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01221-18

Reference32 articles.

1. Centers for Disease Control and Prevention. 2017. Reported STDs in the United States 2016. High burden of STDs threaten millions of Americans. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov/nchhstp/newsroom/docs/factsheets/STD-Trends-508.pdf.

2. Centers for Disease Control and Prevention. 2017. Sexually transmitted diseases surveillance 2016. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov/std/stats16/CDC_2016_STDS_Report-for508WebSep21_2017_1644.pdf.

3. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

4. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action

5. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The overview of development of novel bacterial topoisomerase inhibitors effective against multidrug-resistant bacteria in an academic environment: From early hits to in vivo active antibacterials;European Journal of Pharmaceutical Sciences;2024-01

2. Neisseria gonorrhoeae;Molecular Medical Microbiology;2024

3. Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study;The Lancet Microbe;2023-10

4. Challenges and Solutions to STI Control in the Era of HIV and STI Prophylaxis;Current HIV/AIDS Reports;2023-09-26

5. Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study;Infectious Diseases and Therapy;2023-09